This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is HOLX Stock a Smart Hold for Your Portfolio Right Now?
by Zacks Equity Research
Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.
VRNOF Stock Likely to Gain From Its Newly Opened Dispensary in Phoenix
by Zacks Equity Research
Verano is set to open a new Zen Leaf Arcadia in Phoenix, AZ, today. Zen Leaf Arcadia is located at 2710 E Indian School Road, Phoenix. It will be open daily from 8 a.m. to 10 p.m. local time.
Favorable Data on Swoop Portable MRI Likely to Support Hyperfine Stock
by Zacks Equity Research
Compared to conventional MRI, which takes an average of 27.7 hours, the Swoop system of HYPR operates with a median time-to-scan of 2.5 hours.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
by Zacks Equity Research
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
Here's Why You Should Add HAE Stock in Your Portfolio Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics.
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
by Zacks Equity Research
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
by Zacks Equity Research
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
Should You Continue to Retain LH Stock in Your Portfolio?
by Zacks Equity Research
Labcorp's expanding testing solutions in high-growth areas, partnerships and focus on operational efficiency instill optimism.
QGEN Stock Might Rise on Partnership With Bode for GEDmatch PRO
by Zacks Equity Research
QIAGEN announces exclusive global commercial partnership with Bode Technology. Per the agreement, Bode will manage all commercial transactions for QIAGEN's GEDmatch PRO globally.
Reasons to Retain Alcon Stock in Your Portfolio for Now
by Zacks Equity Research
Strong growth in the Surgical and Vision Care businesses raises investors' optimism for ALC.
STIM Stock Likely to Gain From Updated TMS Coverage
by Zacks Equity Research
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage.
TNDM Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for people living with the condition.
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
by Zacks Equity Research
When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.
BiomX Stock Gains From Favorable Study Data Presentation on BX004
by Zacks Equity Research
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept. 28.
VERO Stock Likely to Get Support From New Regulatory Nod in Australia
by Zacks Equity Research
The latest approval for Venus Concept in Australia reinforces its position as a global player in the aesthetic technology space.
Abbott Stock Hurt by Macroeconomic Issues & FX Headwind
by Zacks Equity Research
Foreign exchange fluctuation is a major headwind for ABT, as a considerable percentage of its revenues comes from outside the United States.
QGEN Stock Likely to Gain From Newly Launched Assays for QIAcuity
by Zacks Equity Research
QIAGEN launches 100 new assays for QIAcuity. The newly launched assays are now available through the company???s GeneGlobe platform.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
Is Teleflex Stock a Smart Option for Your Portfolio Right Now?
by Zacks Equity Research
TFX instils optimism with its robust performance in the Interventional category and potential in Asia.
BSX Gets FDA Nod on INGEVITY+ Pacing Lead in the LBBA: Stock to Gain?
by Zacks Equity Research
Boston Scientific received FDA approval on the expanded indication for INGEVITY+ Pacing Leads. Data demonstrated this lead to be safe and effective for LBBA pacing.
Is Phibro Stock Worth Retaining in Your Portfolio Now?
by Zacks Equity Research
PAHC Animal Health business, supported by the flourishing vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health
by Zacks Equity Research
LH completes the acquisition of BioReference Health, a wholly-owned subsidiary of OPKO Health. The acquisition includes BioReference Health's laboratory testing businesses.
QGEN Stock Likely to Gain From Innovation Amid Competition
by Zacks Equity Research
To support internal growth, QIAGEN invests heavily in research and development for the menu expansion of its key platforms.
DGX Stock Likely to Gain From Allina Health's Select Lab Assets Buyout
by Zacks Equity Research
With the completion of the acquisition, Allina Health's clinic physicians will now have access to Quest Diagnostics' laboratory services.
Should You Continue to Retain MYGN Stock in Your Portfolio?
by Zacks Equity Research
Myriad Genetics is advancing with strategic priorities, and bringing new products and upgrades to the market, positively influencing investors' sentiment.